^
Association details:
| Biomarker: | MGMT promoter methylation |
|---|---|
| Cancer: | Glioma |
| Drug: | Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I study of ruxolitinib with radiation and temozolomide in patients with newly diagnosed grade III gliomas and glioblastoma.
Published date:
05/19/2021
Excerpt:
Patients with methylated MGMT glioblastoma or grade III glioma were eligible for Arm 2....The median OS and PFS were 18.2 (95% CI: 3.6-NA) months for Arm 1 and were not reached for Arm 2. OS and PFS Rate at 1 year was 61% (95% CI: 43-85%) and 51% (35-76%) for Arm 1, and 95% (85-100%) for Arm 2 (p = 0.01 and p = 0.002), respectively....Patients that received ruxolitinib + radiation x 60 Gy + daily temozolomide at 75 mg/m2 for 6 weeks over 6 weeks (Arm 2) had significantly better PFS and OS...
Secondary therapy:
temozolomide
DOI:
10.1200/JCO.2021.39.15_suppl.2060
Trial ID:
